C07J 43/006
Spiro-condensed
Official title: {spiro-condensed}
C07J43/006 (Spiro-condensed) appears on 50 US grants and 17 published applications in this corpus.
Search patents in C07J- Granted patents
- 50
- Published applications
- 17
- Assignees
- 25
- Inventors
- 107
- Latest grant
- 24 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 3 | 0 |
| 1986 | 3 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 9 | 0 |
| 1999 | 6 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 3 |
| 2015 | 0 | 1 |
| 2016 | 3 | 3 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 2 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 2 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Coumarin-modified androgens for the treatment of prostate cancer24 Jun 2025US 12,337,004 B2Health Research, Inc.
- Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof22 Apr 2025US 12,281,140 B2Enanta Pharmaceuticals, Inc.
- Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof8 Aug 2023US 11,718,641 B2Enanta Pharmaceuticals, Inc.
- Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD1027 Jul 2021US 11,072,632 B2Universite Laval
- Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof6 Apr 2021US 10,968,249 B2Enanta Pharmaceuticals, Inc.
- Coumarin-modified androgens for the treatment of prostate cancer30 Apr 2026US 2026/0115207 A1Health Research, Inc.
- Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof2 May 2024US 2024/0140984 A1Enanta Pharmaceuticals, Inc.
- Prodrugs of fulvestrant4 May 2023US 2023/0137764 A1Kashiv Biosciences, LLC
- Coumarin-modified androgens for the treatment of prostate cancer14 Jul 2022US 2022/0218722 A1Health Research, Inc.
- Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof26 Aug 2021US 2021/0261600 A1Enanta Pharmaceuticals, Inc.
Most cited
By later US patents
- 11.beta.-arylestradienes, their production, and pharmaceutical preparations containing same39US 4,609,651 ASchering Corporation · 1986
- Therapeutic methods and delivery systems utilizing sex steroid precursors37US 5,728,688 AEndoreoherche, Inc. · 1998
- 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties29US 6,020,328 AResearch Triangle Institute · 2000
- Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone25US 5,776,923 AEndorecherche, Inc. · 1998
- 11.beta.-aryl estradienes, processes for their production and pharmaceutical preparations containing them23US 4,536,401 ASchering Corporation · 1985